{"title":"Antemortem diagnostic tests and treatment outcomes using ivermectin in 13 cases of presumptive feline neurocuterebriasis.","authors":"Xin Yu Wei Chen, Fiona M K James","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Limited reports exist on the antemortem presumptive diagnosis and treatment of feline neurocuterebriasis. A 3-day treatment protocol reported for 3 cats had no adverse effects. This protocol comprised ivermectin (0.4 mg/kg), diphenhydramine (4 mg/kg), and dexamethasone (0.1 mg/kg) given q24h.</p><p><strong>Objective: </strong>To describe the treatment outcomes for cats that received the 3-day ivermectin protocol and antemortem diagnostic methods used before.</p><p><strong>Animals and procedure: </strong>Medical records from a single veterinary referral centre were searched to identify cats treated with the 3-day protocol. Variables extracted included signalment, season, history, neurological examination findings, and advanced diagnostic tests, as well as outcomes based on follow-up.</p><p><strong>Results: </strong>Thirteen cats were diagnosed based on advanced imaging. Ten of 13 also underwent cerebrospinal fluid analysis. Other diagnostic factors included season (July through September), signalment (young to middle-aged), lifestyle (outdoor access), history (7/13 cats showed upper respiratory signs preceding neurological deficits), and clinical signs (central neurological deficits). After being treated with the 3-day ivermectin protocol, 10/13 cats improved. Three cats were euthanized after showing worsening clinical signs.</p><p><strong>Conclusion and clinical relevance: </strong>Outcomes using the 3-day ivermectin protocol appeared favorable. This provided insight about a treatment option for a periodic cause of feline encephalomyelopathy that has potential for deployment in first-opinion practice.</p>","PeriodicalId":9429,"journal":{"name":"Canadian Veterinary Journal-revue Veterinaire Canadienne","volume":"66 1","pages":"64-69"},"PeriodicalIF":0.9000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705184/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Veterinary Journal-revue Veterinaire Canadienne","FirstCategoryId":"97","ListUrlMain":"","RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Limited reports exist on the antemortem presumptive diagnosis and treatment of feline neurocuterebriasis. A 3-day treatment protocol reported for 3 cats had no adverse effects. This protocol comprised ivermectin (0.4 mg/kg), diphenhydramine (4 mg/kg), and dexamethasone (0.1 mg/kg) given q24h.
Objective: To describe the treatment outcomes for cats that received the 3-day ivermectin protocol and antemortem diagnostic methods used before.
Animals and procedure: Medical records from a single veterinary referral centre were searched to identify cats treated with the 3-day protocol. Variables extracted included signalment, season, history, neurological examination findings, and advanced diagnostic tests, as well as outcomes based on follow-up.
Results: Thirteen cats were diagnosed based on advanced imaging. Ten of 13 also underwent cerebrospinal fluid analysis. Other diagnostic factors included season (July through September), signalment (young to middle-aged), lifestyle (outdoor access), history (7/13 cats showed upper respiratory signs preceding neurological deficits), and clinical signs (central neurological deficits). After being treated with the 3-day ivermectin protocol, 10/13 cats improved. Three cats were euthanized after showing worsening clinical signs.
Conclusion and clinical relevance: Outcomes using the 3-day ivermectin protocol appeared favorable. This provided insight about a treatment option for a periodic cause of feline encephalomyelopathy that has potential for deployment in first-opinion practice.
期刊介绍：
The Canadian Veterinary Journal (CVJ) provides a forum for the discussion of all matters relevant to the veterinary profession. The mission of the Journal is to educate by informing readers of progress in clinical veterinary medicine, clinical veterinary research, and related fields of endeavor. The key objective of The CVJ is to promote the art and science of veterinary medicine and the betterment of animal health.
A report suggesting that animals have been unnecessarily subjected to adverse, stressful, or harsh conditions or treatments will not be processed for publication. Experimental studies using animals will only be considered for publication if the studies have been approved by an institutional animal care committee, or equivalent, and the guidelines of the Canadian Council on Animal Care, or equivalent, have been followed by the author(s).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
